mutation are insensitive to EGFR-TKIs in the clinical setting (2–10) (ii) a clinically relevant efficacy of EGFR-TKI is reported in another 10% of non squamous NSCLC without any EGFR mutation [14,15], (iii) EGFR mutation status may be unknown at the time of treatment initiation, (iv) a systematic EGFR testing of all NSCLC remains expensive and time-consuming. Here, EGFR is linked to non-small cell lung carcinoma.